Otsuka (OTCMKTS:OTSKY) Sees Large Volume Increase – Time to Buy?

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) shares saw unusually-high trading volume on Friday . Approximately 38,839 shares traded hands during mid-day trading, an increase of 2% from the previous session’s volume of 38,163 shares.The stock last traded at $31.92 and had previously closed at $32.40.

Analyst Ratings Changes

OTSKY has been the topic of a number of recent research reports. Zacks Research upgraded shares of Otsuka from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 31st. The Goldman Sachs Group lowered shares of Otsuka from a “strong-buy” rating to a “strong sell” rating in a research note on Friday, February 27th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Otsuka has a consensus rating of “Hold”.

Otsuka Trading Down 1.3%

The company has a debt-to-equity ratio of 0.05, a current ratio of 2.17 and a quick ratio of 1.67. The business’s 50 day moving average price is $34.77 and its 200-day moving average price is $32.28. The firm has a market capitalization of $34.36 billion and a price-to-earnings ratio of 13.50.

Otsuka (OTCMKTS:OTSKY) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.16. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. The business had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. Equities analysts forecast that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.99 EPS for the current fiscal year.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.